Get started
Author

Peter B. Kirk

Observed names: P. Kirk, Peter Kirk
ORCID: 0000-0001-8657-2090
Observed ORCID: 0000-0001-8657-2090
OpenAlex ID: A5108833504
CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression
2000 · P. Kirk, M.C. Wilson, et al. · The EMBO Journal · 715
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
2016 · Deborah H. Charych, Ute Hoch, et al. · Clinical Cancer Research · 414
Production of therapeutic proteins in algae, analysis of expression of seven human proteins in the chloroplast of Chlamydomonas reinhardtii
2010 · Beth A. Rasala, Machiko Muto, et al. · Plant Biotechnology Journal · 278
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
2017 · Deborah Charych, Samira Khalili, et al. · PLoS ONE · 157
PDF
NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
2021 · Takahiro Miyazaki, Mekhala Maiti, et al. · Journal for ImmunoTherapy of Cancer · 62
PDF
NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases
2021 · Neha Dixit, Christie Fanton, et al. · Journal of Translational Autoimmunity · 60
PDF
A novel form of the membrane protein CD147 that contains an extra Ig-like domain and interacts homophilically
2003 · S Melanie Hanna, Peter Kirk, et al. · BMC Biochemistry · 57
PDF
Pathogen Recognition: TLRs Throw Us a Curve
2005 · Peter Kirk, J. Fernando Bazan · Immunity · 49
PDF
Tuning the potency and selectivity of ImmTAC molecules by affinity modulation
2023 · Ian B Robertson, Rachel Mulvaney, et al. · Clinical & Experimental Immunology · 22
PDF
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific
2025 · Joseph J. Sacco, Peter Kirk, et al. · Cell Reports Medicine · 19
Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM).
2024 · Omid Hamid, Anja Williams, et al. · Journal of Clinical Oncology · 18
PDF
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
2016 · Casey Ager, Matthew Reilley, et al. · Journal for ImmunoTherapy of Cancer · 17
PDF
91P Phase I dose escalation of IMC-C103C, a CD3×MAGE-A4 T-cell receptor (TCR) bispecific protein
2021 · D. Davar, R.F. Sweis, et al. · Annals of Oncology · 7
Abstract 1603: NKTR-255 engages the IL-15 pathway driving CD8 T cell survival and CD8 memory T cell proliferation
2017 · Peiwen Kuo, Mekhala Maiti, et al. · Cancer Research · 7
Co-localization of immunoglobulin superfamily member CD147 with a monocarboxylate transporter (MCT1)
1999 · Marieangela C. Wilson, Catherine Heddle, et al. · Bristol Research (University of Bristol) · 3
694 Phase 1 safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM)
2024 · Diwakar Davar, Anja Williams, et al. · Journal for ImmunoTherapy of Cancer · 2
959 Tebentafusp controls disease and prolongs survival by increasing the T cell: tumor cell ratio, activating T cells and inhibiting tumor proliferation in metastatic uveal melanoma patients
2025 · Adel Benlahrech, James Clubley, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
1177 Phase 1 evaluation of brenetafusp alone and in combination with tebentafusp in metastatic uveal melanoma
2026 · Alexander N Shoushtari, Marlana Orloff, et al. · Journal for ImmunoTherapy of Cancer
PDF
Phase 1 evaluation of the PRAME-targeted ImmTAC brenetafusp in advanced melanoma (Mel).
2026 · Georgina V. Long, Diwakar Davar, et al. · Journal of Clinical Oncology
Effect of IL7 on ImmTAC-mediated killing by T cells in vitro and T-cell fitness in patients.
2026 · Joseph J. Sacco, Anna Broomfield, et al. · Journal of Clinical Oncology
PDF
1070 Single cell analysis of a T cell fitness signature associated with clinical benefit from brenetafusp, a PRAME x CD3 T cell engager
2024 · Anastasiya Kazachenka, Laura Collins, et al. · Journal for ImmunoTherapy of Cancer
Data from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
2023 · Deborah H. Charych, Ute Hoch, et al.
Figure S1 from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
2023 · Deborah H. Charych, Ute Hoch, et al.
Figure S3 from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
2023 · Deborah H. Charych, Ute Hoch, et al.
Supplemental Data from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
2023 · Deborah H. Charych, Ute Hoch, et al.
Works count: 33
Citation count: 1,888
H-index: 12
I10-index: 12
Year
Topic
Type